Amorfix Life Sciences has entered into a collaboration with CNJ Holdings, a subsidiary of Cangene Corp., for the identification and development of therapeutic antibodies against disease specific epitopes (DSEs) for oncology indications, using Amorfix's ProMIS discovery technology. The terms were not disclosed.
"This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify and develop novel antibody therapeutics for the treatment of cancer," said Dr. Robert Gundel, Amorfix president and chief executive officer. "Establishing partnerships and strategic alliances to accelerate the discovery, development and commercialization of therapeutic antibodies is part of our overall strategy to build our product pipeline."
"We are excited about this collaboration with Amorfix which brings new energy to our R&D pipeline development efforts," said John Sedor, Cangene's president and chief executive officer. "This is an opportunity to leverage our core competencies to accelerate the development of therapeutic antibodies to novel targets in the oncology space.”